← FDA DRUG APPROVALS

FDA ANDA · ANDA065156

MINOCYCLINE HYDROCHLORIDE

Sponsor: TORRENT

APPLICATION
ANDA065156
TYPE
ANDA
ORIGINAL APPROVAL
2004-01-06
LATEST ACTION
2020-04-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MINOCYCLINE HYDROCHLORIDEPrescription
MINOCYCLINE HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL
MINOCYCLINE HYDROCHLORIDEPrescription
MINOCYCLINE HYDROCHLORIDE EQ 50MG BASE · TABLET · ORAL
MINOCYCLINE HYDROCHLORIDEPrescription
MINOCYCLINE HYDROCHLORIDE EQ 75MG BASE · TABLET · ORAL

Approval history

2020-04-06Labeling · Supplement 17 · standardAP
2020-04-06Labeling · Supplement 15 · standardAP
2012-05-11Labeling · Supplement 10 — Review ↗AP
2008-10-27Labeling · Supplement 8AP
2004-06-23Labeling · Supplement 3AP
2004-01-06Original — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →